Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

January 5, 2016 5 January, 2016

Sernova Corp to Present at the Biotech Showcase™ 2016 in San Francisco on January 13, 2016

Source: Sernova Corp January 6, 2016, 6:00 a.m. EDT

LONDON, Ontario, January 6, 2016– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California. In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.

This conference occurs during the largest gathering of biopharmaceutical executives at parallel conferences in San Francisco which includes the J.P. Morgan Healthcare Conference which itself is the largest healthcare investment symposium in the industry, bringing together global industry leaders, emerging companies, technology innovators and members of the investment community. “Bio-Showcase is viewed as a preeminent gathering for leading life science professionals and brings about major global partnerships and advancements. It is considered an important and timely event for the company as investors, funds, institutions and pharma attend to explore collaborations with an eye to consolidate assets for global market opportunities,” remarked Dr. Toleikis.

About Biotech Showcase(TM)

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential partners in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives Now in its eighth year, Biotech Showcase is expected to attract upwards of 2,000 attendees. The meeting is being held January 11-13, 2016 in San Francisco, CA at the Parc 55, San Francisco, California.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.